NCT02876393

Brief Summary

Diabetic retinopathy(DR) is a sight threatening condition that occurs in persons with diabetes. DR arises as a consequence of damage to the retinal blood vessels and is related to the high and fluctuating sugar levels in the blood stream. An eye with DR will have abnormal appearing retinal blood vessels which become engorged and dilated, leaky and fragile or undergo closure. The net result is a picture of haemorrhage and or ischaemia (lack of blood supply). A particular feature of DR is the accumulation of fluid in the macula which is the central part of the retina and responsible for detailed eye sight. This peculiar form of DR is called Diabetic Macular Oedema (DMO). DMO can occur in isolation without other features of DR. DMO is commoner in type 2 diabetes where insulin resistance and abnormalities of blood fats are found. The investigators wish to study DR and DMO using high resolution retinal imaging and functional tests in normal participants, those participants with diabetes without any overt signs of disease and those with DR and DMO in order to understand how the condition develops and whether there are any unique risk factors that can be identified

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
172

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Nov 2014

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2014

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

April 28, 2016

Completed
4 months until next milestone

First Posted

Study publicly available on registry

August 23, 2016

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2017

Completed
Last Updated

April 4, 2019

Status Verified

April 1, 2019

Enrollment Period

2.2 years

First QC Date

April 28, 2016

Last Update Submit

April 2, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Presence of DMO evaluated from the optical coherence tomography (OCT) images

    The outcome measures will be assessed at the end of 3 months

Study Arms (2)

Cases

Persons with type 1 or type 2 DM with features of DR and or DMO ranging from extremely mild to severe.

Control definition

Persons with a history of type 1 or type 2 DM without any clinical features of DR or DMO in either eye or persons without a history of DM and without retinal disease in either eye.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Potential participants with DR of different severity levels ranging from minimal DR to severe DR with or without DMO who attend the diabetic clinics will be invited to participate. Opportunistic sampling will be used to ensure that the different severity levels of DR and or DMO will be adequately represented.The Northern Ireland Cohort Longitudinal Study On ageing (NICOLA), a non-interventional epidemiological study of healthy ageing in older adults aged 50 years and above has commenced and is currently recruiting some 8500 participants. Participants in NICOLA who are known to have DM or have been recently diagnosed with DM will be approached and asked if willing to return for detailed functional testing of the eye. This will supplement the group with DM but with no changes of DR. Control participants with DM but without DR will be recruited from the metabolic clinics of the Belfast Trust.

You may qualify if:

  • Group 1 (Healthy controls without DM):
  • Persons older than 18 years without DM
  • Fundus free of any signs of retinal disease
  • Best Corrected Visual Acuity of 20/40 (73 ETDRS letters) in both eyes
  • Group 2 (Persons with DM with no retinopathy):
  • Persons with Type 1 or type 2 diabetes older than 18 years
  • Normal fundus, Absence of features of DR or DMO in both eyes
  • Best Corrected Visual Acuity 20/40 (73 ETDRS letters) in at least one eye
  • Group 3:
  • Persons with Type 1 or type 2 diabetes 18 years and older
  • Fundus signs of mild, moderate or severe DR and or DMO
  • Best Corrected Visual Acuity 20/200 (33 ETDRS letters) or better

You may not qualify if:

  • Recent ocular surgical procedures performed within the previous 3 months
  • Presence of ocular confounding disorders such as neovascular age related macular degeneration, glaucoma or active uveitis
  • Serious life threatening conditions that would preclude attendance in the longitudinal part of the study
  • Neurological conditions that can impair vision

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

NI clinical Research Facility,51 Lisburn Road

Belfast, BT9 7AB, United Kingdom

Location

MeSH Terms

Conditions

Diabetes MellitusDiabetic Retinopathy

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesRetinal DiseasesEye DiseasesDiabetic AngiopathiesVascular DiseasesCardiovascular DiseasesDiabetes Complications

Study Officials

  • Prof Usha Chakravarthy, Phd FRCopth

    Queens University Belfast

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

April 28, 2016

First Posted

August 23, 2016

Study Start

November 1, 2014

Primary Completion

January 1, 2017

Study Completion

January 1, 2017

Last Updated

April 4, 2019

Record last verified: 2019-04

Locations